Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-3512676 with Paclitaxel, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC
NCT00313768Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2005
- Primary completion
- May 2008
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of agatolimod in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2005; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00313768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313768.